The unit invested $145 million in Aimmune in 2016, followed by $30 million as part of the drugmaker's public offering in February 2018, and another $98 million in November 2018. Aimmune would use the latest Nestle investment to fund the launch of Palforzia, which is the first approved therapy for reducing and potentially eliminating allergic reactions to peanuts in children. Baird analyst Brian Skorney suspects a potential for short squeeze as some decide to cover rather than wait for the performance of Palforzia in the first couple of quarters against modest expectations. Short interest, a measure of how much money is betting on the stock to go lower, in Aimmune stood at nearly 25% of the float, as of Jan. 15, according to Refinitiv data. Shares of heavily shorted companies can get pushed higher as traders rush to buy stock to cover their short bets, triggering what is known as a "short squeeze".